Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

Inclisiran, a small interfering RNA that targets PCSK9 mRNA, was given as a single injection at baseline or in two doses at baseline and 90 days. At 180 days, LDL cholesterol was significantly lowered among persons at high cardiovascular risk who had elevated levels at baseline. Low-density lipoprot...

Full description

Saved in:

Bibliographic Details
Published in:	The New England journal of medicine Vol. 376; no. 15; pp. 1430 - 1440
Main Authors:	Ray, Kausik K, Landmesser, Ulf, Leiter, Lawrence A, Kallend, David, Dufour, Robert, Karakas, Mahir, Hall, Tim, Troquay, Roland P.T, Turner, Traci, Visseren, Frank L.J, Wijngaard, Peter, Wright, R. Scott, Kastelein, John J.P
Format:	Journal Article
Language:	English
Published:	United States Massachusetts Medical Society 13.04.2017
Subjects:	Aged Anticholesteremic Agents - administration & dosage Anticholesteremic Agents - adverse effects Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - prevention & control Cholesterol Cholesterol, LDL - blood Dose-Response Relationship, Drug Double-Blind Method Female Gene expression Humans Hypercholesterolemia - drug therapy Injection Injections, Subcutaneous Kexin Low density lipoprotein Male Middle Aged mRNA Proprotein Convertase 9 - antagonists & inhibitors Proprotein Convertase 9 - blood Proprotein convertases Risk Factors RNA, Small Interfering - administration & dosage RNA, Small Interfering - adverse effects siRNA Statins Subtilisin Transaminases - blood
ISSN:	0028-4793, 1533-4406
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!